Fundraising Fox
/Companies
Sign in

Repertoire Immune Medicines

Founded 2020 · 84 employees on LinkedIn · 3 known investors

Find your way into Repertoire Immune Medicines

Sign up to see every warm intro you have to Repertoire Immune Medicines

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Repertoire Immune Medicines team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Repertoire's Decode platform focuses on mapping the immune synapse — the interactions between T cell receptors, epitopes, and HLA molecules — to support the development of medicines targeting cancer and other diseases. It operates in immunology-based drug discovery and therapeutics.

AI & Machine LearningBiotechDeep TechDigital HealthHealthtech

Founders & leadership

TSTorben Straight Nissen
Torben Straight NissenChief Executive OfficerVenture Partner at Flagship Pioneering
ACAnthony Coyle
Anthony CoylePresident, Research and DevelopmentDr. Anthony Coyle is President of Research and Development at Repertoire Immune Medicines and formerly founded Pandion Therapeutics, a biotech company developing autoimmune therapies that raised $58 million in Series A funding. He has held leadership positions in drug discovery at Pfizer, MedImmune/AstraZeneca, Millennium Pharmaceuticals, and the Glaxo Institute, with expertise spanning immunology, inflammation research, and translating early-stage science into clinical programs; he holds a first-class honors degree from King's College, University of London, and has authored over 200 peer-reviewed publications.
RARobert Andtbacka
Robert AndtbackaChief Medical Officer
JDJohn Delyani
John DelyaniChief Business OfficerJohn Delyani holds a PhD and MBA and brings two decades of operational experience in corporate strategy, business development, and corporate development across biotech and pharmaceutical companies. He has led execution of over 40 business agreements and serves as Chief Business Officer of Repertoire Immune Medicines.
JKJan Kisielow
Jan KisielowChief Scientific Officer, Repertoire Immune Medicines (Switzerland) Ltd.

Investors · 3

SoftBank Vision Fundlisted by SoftBank Vision FundLondon
JDRF T1D FundreportedBoston

How we know: funding news · press coverage · Not right? Tell us

Founder mafia

4 people who came through Repertoire Immune Medicines went on to found or lead other companies.

Noubar AfeyanBoard Member and Co-FounderFounded ProFound Therapeutics +15John G. CoxChief Executive Officer Repertoire Immune MedicinesFounded Torque Therapeutics +1Anthony CoylePresident, Research and DevelopmentFounded Pandion TherapeuticsTorben Straight NissenChief Executive OfficerFounded Etiome

Frequently asked questions

What does Repertoire Immune Medicines do?
Repertoire's Decode platform focuses on mapping the immune synapse — the interactions between T cell receptors, epitopes, and HLA molecules — to support the development of medicines targeting cancer and other diseases. It operates in immunology-based drug discovery and therapeutics.
Who are Repertoire Immune Medicines's investors?
Repertoire Immune Medicines's investors include Flagship Pioneering, SoftBank Vision Fund, JDRF T1D Fund.